Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, interviews Ulrich Neumann, MBA, MSc, MA, Director of Access and Policy Research at Johnson & Johnson, to discuss the motivation behind the recent launch of the J&J Center for U.S. Healthcare Policy Research, the interconnectedness and importance of the various players within the biopharmaceutical R&D ecosystem, and the private capital that is required to develop new drugs.

Resources mentioned in this episode:

https://policyresearch.jnj.com

https://jnjinnovation.com/home

https://www.nature.com/articles/d41573-024-00131-2

https://www.ispor.org/docs/default-source/intl2024/j-j-access-policy-research---ispor-2024---pharma-r-d-ecosystem-investment137860-pdf.pdf?sfvrsn=d28181d4_0

https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2405407